Literature DB >> 18308439

Exploring emerging technologies using metaphors--a study of orphan drugs and pharmacogenomics.

Wouter Boon1, Ellen Moors.   

Abstract

Due to uncertainties of several aspects of emerging health technologies, there is a need to anticipate these developments early. A first step would be to gather information and develop future visions about the technology. This paper introduces metaphor analysis as a novel way to do this. Specifically, we study the future of pharmacogenomics by comparing this technology with orphan drugs, which are more established and often act as a model with comparable (economic, research organisation, etc.) characteristics. The analysis consists of describing the dominant metaphors used and structurally exploring (dis)similarities between pharmacogenomics and orphan drugs developments. This comparison leads to lessons that can be learnt for the emerging pharmacogenomics future. We carried out a comprehensive literature review, extracting metaphors in a structured way from different areas of the drug research and development pipeline. The paper argues that (1) there are many similarities between orphan drugs and pharmacogenomics, especially in terms of registration, and social and economic impacts; (2) pharmacogenomics developments are regarded both as a future 'poison' and a 'chance', whereas orphan drugs are seen as a 'gift', and at the same time as a large 'problem'; and (3) metaphor analysis proves to be a tool for creating prospective images of pharmacogenomics and other emerging technologies.

Mesh:

Year:  2008        PMID: 18308439     DOI: 10.1016/j.socscimed.2008.01.012

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  6 in total

Review 1.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

2.  Pricing and reimbursement of orphan drugs: the need for more transparency.

Authors:  Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2011-06-17       Impact factor: 4.123

Review 3.  Rare diseases and orphan drugs: Latvian story.

Authors:  Konstantins Logviss; Dainis Krievins; Santa Purvina
Journal:  Orphanet J Rare Dis       Date:  2014-09-18       Impact factor: 4.123

4.  A multi-level model of emerging technology: An empirical study of the evolution of biotechnology from 1976 to 2003.

Authors:  Ad van den Oord; Arjen van Witteloostuijn
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

5.  Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.

Authors:  Conor M W Douglas; Fernando Aith; Wouter Boon; Marina de Neiva Borba; Liliana Doganova; Shir Grunebaum; Rob Hagendijk; Larry Lynd; Alexandre Mallard; Faisal Ali Mohamed; Ellen Moors; Claudio Cordovil Oliveira; Florence Paterson; Vanessa Scanga; Julino Soares; Vololona Raberharisoa; Tineke Kleinhout-Vliek
Journal:  Orphanet J Rare Dis       Date:  2022-09-05       Impact factor: 4.303

6.  Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine.

Authors:  Shannon Gibson; Hamid R Raziee; Trudo Lemmens
Journal:  World Med Health Policy       Date:  2015-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.